(ACS), the term “pre-treatment” usually refers to the practice of initiating dual antiplatelet
therapy, in particular an oral P2Y12 inhibitor in adjunct to aspirin, before performing the …

1892 Circulation November 18, 2014 who were hospitalized within 24 hours after the onset
of symptoms. 9 A loading dose of clopidogrel (300 mg) or placebo was administered …

The value of pre-treatment with an oral P2Y12 receptor inhibitor (in addition to aspirin), that
is, its administration prior to coronary angiography and defining the coronary anatomy, in …

The oral P2Y12 inhibitors prasugrel and ticagrelor have demonstrated biological and clinical
superiority over clopidogrel, with a faster onset of action and greater potency, which …

Pre-treatment with an oral P2Y12 receptor inhibitor in addition to aspirin is defined by its
administration to every patient before coronary angiography, which will (or not) confirm the …

Background Although P2Y12 antagonists are effective in patients with non–ST-segment
elevation (NSTE) acute coronary syndromes, the effect of the timing of administration …

Abstract Background Although oral P2Y12 inhibitors are key in the management of patients
with non–ST-segment elevation acute coronary syndrome, the optimal timing of their …

The analysis of the evidence that formed the basis for the current guidelines of the European
Society of Cardiology (ESC) on oral therapy by antithrombotic drugs for acute coronary …

Prasugrel is now the preferred choice of P2Y12 receptor inhibitor for dual antiplatelet
therapy with Aspirin for patients undergoing coronary intervention. It is now recommended …

Collet et al Pretreatment in NSTE-ACS 1905 bleeding events among patients receiving PCI.
9 However, the timing of loading was not tested in these pivotal trials. It remained a matter of …